Registration for a live webinar on 'Innate immunity, inflammation and cancer' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Evolutionary Perspectives
-
1. Antibiotic resistance: a mechanistic overview
- Dr. Neil Woodford
-
2. Mutation
- Prof. Stephen Gillespie
-
3. Fitness in antibiotic resistant bacteria
- Prof. Stephen Gillespie
-
4. Fitness and compensation
- Dr. Sébastian Gagneux
-
5. Antibiotic resistance and the supragenome hypothesis
- Dr. Bambos Charalambous
- Epidemiology and Clinical Impact
-
6. Methicillin resistant S. aureus and other resistances
- Prof. Mark Enright
-
7. Risk factors for antibiotic resistance in Streptococcus pneumoniae
- Prof. Keith Klugman
-
8. Beta-lactamases: clinical impact and epidemiology
- Prof. Sebastian Amyes
-
9. Glycopeptide-resistant enterococci
- Dr. Neil Woodford
-
10. Drug resistant tuberculosis: biology, epidemiology and control
- Dr. Christopher Dye
-
11. Antiretroviral drug resistance
- Prof. Deenan Pillay
-
12. Malaria - changing paradigms
- Dr. Janet Cox-Singh
-
13. Advances in mode of action of antimalarials and resistance mechanisms 1
- Prof. David Warhurst
-
14. Advances in mode of action of antimalarials and resistance mechanisms 2
- Prof. David Warhurst
- Diagnosis and Surveillance of Resistance
-
15. Conventional and automated diagnostic methods
- Dr. Alan Johnson
-
16. National and international surveillance of antibiotic resistance 1
- Prof. David Livermore
-
17. National and international surveillance of antibiotic resistance 2
- Prof. David Livermore
- Controlling Antibiotic Resistance
-
18. Controlling antibiotic resistance in the hospital environment
- Dr. Ian Eltringham
-
19. Controlling antibiotic resistance in the community
- Dr. Peter Wilson
-
20. Public policy to reduce antibiotic resistance
- Dr. Niels Frimodt-Møller
- The Antibiotic Resistance Future
-
21. Overcoming resistance through novel drug targets
- Prof. Anthony Coates
-
22. Medicinal chemistry strategies in combating antibiotic resistance
- Dr. Geoffrey Coxon
-
23. Teixobactin kills pathogens without detectable resistance
- Prof. Kim Lewis
- Archived Lectures *These may not cover the latest advances in the field
-
24. Molecular diagnosis of antibiotic resistance
- Dr. Tim McHugh
-
25. Introduction to malaria
- Prof. David Warhurst
Printable Handouts
Navigable Slide Index
- Introduction
- GRE: where it all began
- Prevalence of GRE in the UK
- GRE bacteraemias, EARSS 2008
- Vancomycin resistant enterococci in the US
- GRE are a localised problem in the UK
- Enterococci as opportunist pathogens
- Risk factors for GRE infection
- The clinical problem with GRE - mutliresistance
- Enterococcus species
- Glycopeptide resistance in enterococci
- Characteristics of glycopeptide resistance
- GRE: primarily E. faecium with VanA
- Glycopeptide action and resistance
- GRE...all because of one critical H-bond
- Regulation of glycopeptide resistance (VanA)
- Cell wall synthesis in GRE
- Glycopeptide dependent enterococci
- Cell wall synthesis in resistant enterococci
- Resistant isolates
- PFGE analysis: the "gold standard" method
- A national epidemic of GRE in the UK?
- Avoparcin and VanA resistance
- MLST of 720 E. faecium isolates
- Hospital-adapted lineages
- Virulence of E. faecalis
- Resistance genes and elements
- Genetic exchange in enterococci
- The van gene clusters of enterococci
- Transposons carry van gene clusters
- A national epidemic of VanA elements?
- VanA elements in the UK
- Origins of resistant enterococci affecting humans
- Diversity among VanA elements
- Transfer of van genes beyond enterococci
- VanA MRSA has arrived
- Glycopeptide MICs for two VRSA strains
- Poor detection of some VRSA
- Glycopeptide-intermediate S. aureus (GISA)
- Biochemical basis of resistance in GISA
- Resistance to new agents: the red queen theory
- Quinupristin-dalfopristin vs. enterococci
- 'Q-D' resistance mechanisms in enterococci
- Linezolid resistance in enterococci
- Development of linezolid resistance
- Linezolid resistance - summary
- Daptomycin: a cyclic lipopeptide
- Daptomycin: mechanism of action
- Daptomycin: resistance issues, E. faecium
- Second generation glycopeptides (1)
- Vancomycin's and teicoplanin's modes of action
- Second generation glycopeptides (2)
- In vitro activity vs. enterococci
- Telavancin vs. GRE
- Potential for a better anti GRE glycopeptide
- Epidemiology of GRE
- Acknowledgements
Topics Covered
- Original description
- Rates of resistance
- Types of infections
- Risk factors
- Resistance profiles of major species
- Types of vancomycin resistance
- Resistance mechanism
- Cell wall structure
- Glycopeptide dependence
- Epidemiological investigation
- Virulence factors
- Van gene clusters
- VanA S. aureus
- VISA
- 'New' anti-GRE agents and resistance
- New glycopeptides
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Woodford, N. (2009, December 31). Glycopeptide-resistant enterococci [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 20, 2024, from https://hstalks.com/bs/1539/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Neil Woodford has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.